Mandate

Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors

Helios Nordic Energy specialises in developing solar farms and batteries to store energy until they become Ready to Build in the Nordics and Baltics.

The acquisition will enable SunMind to further enrich its expertise in renewable solar energy and other sources of renewable energy.

The current owners of Helios will receive an upfront payment of approximately EUR 73 million as well as a substantial earnout component tied to Helios's portfolio of unsold projects stretching over five years from closing.

The acquisition is subject to customary regulatory approvals.

Vinge's team primarily consisted of Peter Sundgren, Martin E Svanberg, Hanna Jansson and Fredrik Löwenclou (M&A), Amelia Rihs (Employment), Johan Cederblad and Lina Österberg (Environmental law), Kristoffer Larsson and Jasdeep Singh (Real Estate), Jolene Reimersson och Mario Saad (Commercial Agreements), Mia Falk (Compliance), David Olander and Lovisa Lewin (Regulatory),  Cecilia Loctander and  Caroline Löv (Transaction Support Coordinators).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026